This week witnessed an optimistic wave sweeping through the biotech sector with several key ETFs performing impressively. The SPDR S&P Biotech ETF (XBI) reported an 11% hike, showing an increase in fund flows by $155.24 million for the week. The iShares Nasdaq Biotechnology ETF (IBB) closed the week with a rise of 8%, while the Direxion Daily S&P Biotech Bull ETF (LABU) traded up by 31%.
While daily updates will take a break from December 26 to January 2, 2023, due to the end-year festivities, rest assured our Weekly Watchlist and Community Newsletters will be delivered on schedule.
We warmly invite your expertise as we commence our 2024 Trend Predictions Survey. As industry professionals and enthusiasts alike, your views contribute significantly toward forecasting trends, identifying potential challenges, and pinpointing catalysts to monitor in the forthcoming year.
Our focus on bringing you exclusive and precise content will remain steadfast in 2024, with careful insights into the potential catalysts impacting the industry. As the new year kicks off, we examine an array of catalysts due for key data releases and regulatory decisions.
A few highlights include:
– An investigative journey into small and mid-cap companies that are currently pre-revenue and pre-commercialization.
– Spotlight on the thriving competition within the race to develop treatments for NASH, Obesity, Alzheimer’s Disease, and other areas of interest.
– In-depth analysis of the catalysts crucial for the developmental success of companies, closely anticipated by investors, and relevant to the treatment of prevalent diseases.
In other news, Compugen Ltd. (NASDAQ: CGEN) revealed a collaboration with Gilead Sciences, Inc. (NASDAQ: GILD) around Compugen’s pre-clinical antibody program targeting IL-18 binding protein, encompassing the promising COM503 drug candidate. As per the agreement, Compugen will manage the ongoing preclinical development and the prospective Phase 1 study of COM503. Gilead will possess exclusive rights for the development and commercialization of COM503.
Invivyd Inc (NASDAQ: IVVD) disclosed preliminary outcomes from the ongoing CANOPY Phase 3 pivotal clinical trial examining VYD222, a monoclonal antibody candidate, showing promising results in its efficacy to prevent symptomatic COVID-19.
Motus GI Holdings, Inc. (NASDAQ: MOTS) announced the cost details of a public offering amounting to $5.0 million. The offer comprises shares of common stock as well as Series A common and Series B common warrants.
TC plc (NASDAQ: TCBP) also released the pricing details for a public offering, comprising American Depositary Shares (ADSs) and associated Series E warrants.
This industry update is brought to you by BioDataStudio.com. Be sure to check out the latest tools and news today.
